摘要
目的评价妥洛特罗贴剂在儿童咳嗽变异性哮喘（CVA）诊断性治疗中的作用,以及妥洛特罗贴剂联合孟鲁司特钠治疗儿童CVA的有效性和安全性。方法选取101例疑似CVA的慢性咳嗽患儿,给予妥洛特罗贴剂诊断性治疗1-2周后,根据咳嗽严重程度评分将其分为诊断性治疗阳性组（A组）和诊断性治疗阴性组（B组）。A组继续给予妥洛特罗贴剂联合孟鲁司特钠治疗2周;B组根据初步诊断,给予相应的药物治疗2周。记录妥洛特罗贴剂在儿童CVA诊断性治疗中的灵敏度、特异度及起效时间,并对A组最终诊断为CVA的患儿进行疗效观察及安全性评价。结果 1妥洛特罗贴剂诊断性治疗儿童CVA的灵敏度为98.78%,特异度为87.50%,平均起效时间为（12.15±2.58）d。2妥洛特罗贴剂联合孟鲁司特钠治疗后,临床控制率较诊断性治疗期显著增高（P〈0.05）,而总有效率有增高趋势。3与基线期相比,妥洛特罗联合孟鲁司特钠治疗对日间及夜间症状均有显著改善（P〈0.05）。4总体用药依从性及用药满意度均较好,不良反应发生率仅为3.06%。结论妥洛特罗贴剂可作为儿童CVA的诊断性治疗药物,诊断性治疗时间以2周为宜。妥洛特罗贴剂联合孟鲁司特钠在治疗儿童CVA上具有协同作用,可达到更好的疗效。
Objective To evaluate the role of tulobuterol patch in the diagnostic therapy for children with cough variant asthma（CVA）,and evaluate the efficacy and safety of tulobuterol patch plus montelukast in the therapy of CVA. Methods 101 children with suspected CVA received diagnostic therapy with tulobuterol patch for 1 -2weeks. Then according to the cough severity score,they were divided into 2 groups：group A（diagnostic therapy positive group） and group B（diagnostic therapy negative group）. Patients in group A received tulobuterol patch plus montelukast for 2 weeks. Patients in group B received medications for 2 weeks according to the empirical diagnosis. The sensitivity,specificity and duration of action onset of tulobuterol patch in diagnostic therapy for children with CVA were evaluated. The efficacy and safety of tulobuterol patch plus montelukast were observed in patients of group A with a final diagnosis of CVA. Results 1The sensitivity and specificity were 98. 78% and 87. 50%,the average duration of action onset was（12. 15 ± 2. 58） d. 2After the treatment of tulobuterol patch plus montelukast,the clinical control rate increased more significantly compared with that in diagnostic therapy period（P〈0. 05）,and the overall effective rate had a tendency to increase. 3 Compared with baseline,the daytime and nighttime symptoms were significantly improved by tulobuterol patch plus montelukast therapy（ P〈0. 05）. 4The compliance and patients＇ satisfaction were good and the rate of adverse effect was 3. 06%. Conclusion Tulobuterol patch can be used in the diagnostic therapy for children with CVA,and the duration should be 2 weeks. Tulobuterol patch plus montelukast has a synergistic effect on children with CVA,which can achieve better effects.
出处
《实用药物与临床》
CAS
2014年第10期1272-1276,共5页
Practical Pharmacy and Clinical Remedies
